Editorial: Epigenetics in Cancer: Mechanisms and Drug Development

Huiqing Yuan; Yongmei Huang; Susu Tao; Biaoru Li; Zhenhua Xu; Yi Qi; Binhua Wu; Hui Luo; Xiao Zhu

doi:10.3389/fgene.2022.831704

Editorial: Epigenetics in Cancer: Mechanisms and Drug Development

Front Genet. 2022 Jun 28:13:831704. doi: 10.3389/fgene.2022.831704. eCollection 2022.

Authors

Huiqing Yuan^{1

2

3}, Yongmei Huang^{2

3

4}, Susu Tao^{2

3

4}, Biaoru Li⁵, Zhenhua Xu⁶, Yi Qi^{2

3

4}, Binhua Wu^{2

3

4}, Hui Luo^{2

3

4}, Xiao Zhu^{1

2}

Affiliations

¹ School of Laboratory Medicine and Biomedical Engineering, Hangzhou Medical College, Hangzhou, China.
² The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, China.
³ Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Zhanjiang, China.
⁴ The Key Lab of Zhanjiang for R&D Marine Microbial Resources in the Beibu Gulf Rim, Guangdong Medical University, Zhanjiang, China.
⁵ Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA, United States.
⁶ Center for Cancer and Immunology, Children's National Health System, Washington, DC, DC, United States.

No abstract available

Keywords: DNA methylation; cancer therapy; epigenetic drugs; histone deacetylation; tumor inhibitors.

Publication types

Editorial